Apatinib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: NMPA Approved
Selectivity scorecard
KISS
97.73
Gini
0.704
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Apatinib. Strongest target: RAF1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RAF1 | 100.0% | 0.0% |
| 2 | C_KIT | 98.9% | 1.1% |
| 3 | FMS | 97.8% | 2.2% |
| 4 | FLT1_VEGFR1 | 95.6% | 4.4% |
| 5 | YSK4_MAP3K19 | 95.3% | 4.7% |
| 6 | BRAF | 94.1% | 5.9% |
| 7 | KDR_VEGFR2 | 92.3% | 7.7% |
| 8 | FLT4_VEGFR3 | 90.8% | 9.2% |
| 9 | ARAF | 90.7% | 9.3% |
| 10 | JAK1 | 88.7% | 11.3% |
| 11 | LYN | 82.3% | 17.7% |
| 12 | TAOK2_TAO1 | 81.5% | 18.6% |
| 13 | RET | 81.1% | 18.9% |
| 14 | DDR2 | 80.9% | 19.1% |
| 15 | PDGFRB | 80.9% | 19.1% |
| 16 | LCK | 71.8% | 28.2% |
| 17 | ZAK_MLTK | 71.1% | 28.9% |
| 18 | HIPK4 | 70.8% | 29.2% |
| 19 | ABL2_ARG | 65.4% | 34.6% |
| 20 | JAK2 | 65.3% | 34.7% |
Selectivity landscape
Where Apatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Apatinib.
Atlas insights for Apatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.824 |
| EPT0291 | EPN | 0.823 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.814 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.811 |
| SRR10899984 | — | 0.808 |
Annotations
Sign in to read and post annotations.
Loading…